Julie Papanek is a healthcare investor at Canaan Partners, a tech and healthcare venture capital firm with $4.2 billion assets under management. Julie brings operational experience from biotechnology and digital health, where she leads investments across those both sectors. She is currently on the board of Protagonist Therapeutics. Julie plays an active role in Canaan’s investments at the intersection of biopharmaceuticals and digital health including Truveris, Glooko and Chrono Therapeutics. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. Julie holds an MBA from Stanford’s Graduate School of Business and earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry. – See more at: http://www.canaan.com/people/julie-papanek/#sthash.ciEG6nUJ.dpuf